» Articles » PMID: 15523393

A Randomized Multicenter Trial Comparing Resection and Radiochemotherapy for Resectable Locally Invasive Pancreatic Cancer

Overview
Journal Surgery
Specialty General Surgery
Date 2004 Nov 4
PMID 15523393
Citations 49
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Though the outcome of resection for locally invasive pancreatic cancer is still poor, it has gradually improved in Japan, and the 5-year survival is now about 10%. However, the advantage of resection over radiochemotherapy has not yet been confirmed by a randomized trial. We conducted this study to compare surgical resection alone versus radiochemotherapy without resection for locally invasive pancreatic cancer using a multicenter randomized design.

Methods: Patients with pancreatic cancer who met our preoperative criteria for inclusion (pancreatic cancer invading the pancreatic capsule without involvement of the superior mesenteric artery or the common hepatic artery, or without distant metastasis) underwent laparotomy. Patients with operative findings consistent with our criteria were randomized into a radical resection group and a radiochemotherapy group (200 mg/m(2)/day of intravenous 5-fluorouracil and 5040 cGy of radiotherapy) without resection. The 2 groups were compared for mean survival, hazard ratio, 1-year survival, quality of life scores, and hematologic and blood chemical data.

Results: Twenty patients were assigned to the resection group and 22 to the radiochemotherapy group. There was 1 operative death. The surgical resection group had better results than the radiochemotherapy group as measured by 1-year survival (62% vs 32 %, P=.05), mean survival time (>17 vs 11 months, P < .03), and hazard ratio (0.46, P=.04). There were no differences in the quality of life score or laboratory data apart from increased diarrhea after surgical resection.

Conclusions: Locally invasive pancreatic cancer without distant metastases and major arterial invasion appears to be best treated by surgical resection.

Citing Articles

Preoperative Prediction of Long-Term Survival After Surgery in Patients with Resectable Pancreatic Ductal Adenocarcinoma.

Konishi T, Takano S, Takayashiki T, Suzuki D, Sakai N, Hosokawa I Ann Surg Oncol. 2024; 31(10):6992-7000.

PMID: 38926210 PMC: 11413041. DOI: 10.1245/s10434-024-15648-4.


Pancreatic Resection for Pancreatic Tumors our Experience at Suburban Hospital.

Nichkaode P, Sharma B, Reddy S, Inturi R Ann Afr Med. 2024; 22(4):537-543.

PMID: 38358158 PMC: 10775925. DOI: 10.4103/aam.aam_165_22.


Radiotherapy for Locally Advanced Pancreatic Adenocarcinoma-A Critical Review of Randomised Trials.

Weisz Ejlsmark M, Schytte T, Bernchou U, Bahij R, Weber B, Mortensen M Curr Oncol. 2023; 30(7):6820-6837.

PMID: 37504359 PMC: 10378124. DOI: 10.3390/curroncol30070499.


Preliminary experience on laparoscopic pancreaticoduodenal combined with major venous resection and reconstruction anastomosis.

Peng X, He Y, Tang Y, Yang X, Huang W, Li J Front Surg. 2022; 9:974214.

PMID: 36157401 PMC: 9492958. DOI: 10.3389/fsurg.2022.974214.


Intraoperative Positive Pancreatic Parenchymal Resection Margin: Is It a True Indication of Completion Total Pancreatectomy after Partial Pancreatectomy for Pancreatic Ductal Adenocarcinoma?.

Jung J, Yoon S, Lee O, Shin S, Heo J, Han I Curr Oncol. 2022; 29(8):5295-5305.

PMID: 36005158 PMC: 9406454. DOI: 10.3390/curroncol29080420.